Novavax, Inc. NVAX
10.63
0.03
0.28%
as of 25 Sep
- Market cap
- $1.8B
- P/E
- 0.0×
Follow NVAX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 323.66% | 79.70% | (117.16%) | (100.06%) |
+8 more TTM periods Free account |
|
| (21.62%) | (7.52%) | 32.17% | 23.63% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(51.76%) | (15.96%) | 78.19% | 57.55% | |
Average Days of Receivables |
16.53 | 14.27 | 34.58 | 11.72 | |
Free Cash Flow per Share |
(0.26) | (0.59) | (1.56) | (1.19) | |
Free Cash Flow |
(42.20) | (96.79) | (252.05) | (193.10) | |
Capital Expenditures |
(5.30) | (5.23) | (7.42) | 185.22 | |
Piotroski F-Score |
1.00 | 1.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(4.49%) | (9.76%) | (28.30%) | (43.83%) | |
Accounts Receivable Turnover |
3.38 | 17.59 | 10.46 | 16.49 | |
Accounts Payable Turnover |
2.41 | 3.57 | 2.21 | 2.41 | |
Inventory Turnover |
8.75 | 8.25 | 7.20 | 7.91 | |
Average Days of Payables |
94.55 | 65.58 | 122.82 | 63.44 | |
Days of Inventory on Hand |
41.25 | 46.67 | 57.69 | 56.29 | |
Tax Rate |
0.01 | 0.02 | 0.00 | (0.03) | |
Research and Development Expense of Revenue |
82.24% | 58.50% | 30.47% | 34.83% | |
Selling, General and Administrative Expense of Revenue |
29.29% | 23.17% | 14.02% | 18.95% | |
Share Based Compensation of Revenue |
7.81% | 5.61% | 3.21% | 3.62% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.15 | 1.04 | (0.56) | (1.11) | |
Depreciation/Fixed assets |
0.47 | 0.53 | 0.62 | 0.71 | |
Capex/Depreciation |
(0.30) | (0.23) | (0.27) | 5.29 | |
Revenue per Share |
2.51 | 3.65 | 6.94 | 6.56 | |
Operating CF per Share |
(0.22) | (0.56) | (1.51) | (2.33) | |
Capex per Share |
(0.03) | (0.03) | (0.05) | 1.14 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | (0.17) | |
Net Profit Margin |
(59.87%) | (14.73%) | 39.19% | 32.10% |
Columns are period end dates